Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 2 |
| Biopharmaceutical Manufacturing in India, China and South Korea - Introduction | 11 | 1 |
| Introduction | 11 | 1 |
| Biopharmaceutical Manufacturing in India, China and South Korea - Overview of the Biopharmaceutical Industry | 12 | 32 |
| Definition and Objective Analysis of Newly Approved Biopharmaceuticals | 12 | 3 |
| Collective Analysis of Biopharmaceuticals Approved in 2010 and 2011 | 15 | 2 |
| Current Scenario in Biopharmaceutical Manufacturing | 17 | 5 |
| Biopharmaceutical Manufacturing | 22 | 1 |
| Factors Driving Outsourcing to India, China and South Korea | 23 | 1 |
| Comparative Cost Analysis between In-House Biopharmaceutical Production Versus Contract Manufacturing Organizations | 23 | 1 |
| Growth Drivers for Contract Research and Manufacturing Services | 24 | 2 |
| Contract Manufacturing Benefits | 26 | 1 |
| Operating Cost Analysis in Biopharmaceutical Manufacturing | 27 | 1 |
| Labor Cost Analysis | 27 | 1 |
| Investment Cost Analysis | 28 | 1 |
| Roche Case Study | 28 | 1 |
| Standard Operating Costs | 29 | 2 |
| Cost and Timeline Analysis for Therapeutic Monoclonal Antibody Product Development | 31 | 3 |
| Manufacturing Equipment Trends | 34 | 1 |
| Comparative Analysis of New and Old Equipment | 35 | 1 |
| Consolidation in Pharmaceutical Industry has Resulted in Idle Production Lines | 36 | 2 |
| Biosimilars in Asia | 38 | 1 |
| CMOs to Benefit by Expanding Operations in Biopharmaceutical Manufacturing | 38 | 1 |
| Trends Witnessed in Biopharmaceutical Manufacturing | 39 | 1 |
| Single-Use Bioprocessing and Microbial Technologies to Dominate Biopharmaceutical Manufacturing | 39 | 1 |
| Biopharmaceutical R&D and Manufacturing Outsourcing to Rise | 39 | 1 |
| Market for Biopharmaceuticals to Rise at Brisk Rate | 39 | 1 |
| Introduction of Biosimilars to Multiply Biopharmaceutical Manufacturers | 39 | 1 |
| R&D Spend in Biopharmaceuticals Insulated from Economic Downturn | 40 | 1 |
| Downstream Processing Technologies Acting as Bottleneck in Biopharmaceutical Manufacturing | 40 | 1 |
| Preferred Biopharmaceutical Contract Pricing Model | 40 | 1 |
| Contract Manufacturing Partnerships | 41 | 2 |
| Comparative Analysis of India, China and South Korea with Reference to Government Initiatives, Investment and Skills | 43 | 1 |
| Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical Manufacturing in India | 44 | 13 |
| Augmentation Potential of Biopharmaceuticals in India | 44 | 1 |
| Stem Cells | 44 | 1 |
| Biosimilars | 44 | 2 |
| Vaccines | 46 | 1 |
| Biopharmaceutical Revenues in India | 47 | 1 |
| Drivers and Barriers for Biopharmaceutical Manufacturing in India | 48 | 1 |
| Proposals to the Government for Promoting Biopharmaceutical Manufacturing | 49 | 1 |
| Pharmaceutical Cluster Development in India | 49 | 1 |
| Regulatory Overview for Biopharmaceuticals in India | 50 | 1 |
| Competitive Landscape | 51 | 1 |
| Biocon Ltd. | 51 | 1 |
| Serum Institute of India Ltd. | 52 | 1 |
| Panacea Biotec Ltd | 53 | 1 |
| Dr. Reddy s | 54 | 1 |
| Cipla | 55 | 1 |
| Lupin | 56 | 1 |
| Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical Manufacturing in China | 57 | 12 |
| Market Size for Chinese Biopharmaceuticals | 57 | 2 |
| Economic Impact of Biopharmaceuticals Approved in China | 59 | 2 |
| Biopharmaceuticals under Progression in China | 61 | 1 |
| Antibodies | 61 | 1 |
| Long-acting Proteins | 61 | 1 |
| Gene Therapy Products | 61 | 1 |
| New vaccines | 61 | 1 |
| Challenges Faced by Biopharmaceuticals in China | 62 | 1 |
| Overproduction of Simpler Drugs is Leading to Over-Competition in Domestic Markets | 62 | 1 |
| Weak Strategic Planning and Management Skills | 62 | 1 |
| Expression Deficit to Limit the Development and Industrialization of Biopharmaceuticals | 62 | 1 |
| Propositions for the Advancement of Biopharmaceuticals in China | 62 | 1 |
| Internationalize the Regulatory System to Eliminate Deficiencies for Biopharmaceutical Products | 62 | 1 |
| Breakthrough Innovation is Critical for the Success of Biopharmaceuticals | 62 | 1 |
| Set up Industrial Standards and Fortify Manufacturing Capacity | 62 | 1 |
| Augment Communication Between Researchers and Clinicians for Developing Biopharmaceuticals | 63 | 1 |
| Contract Manufacturing Scenario in China | 63 | 1 |
| Competitive Landscape | 64 | 1 |
| Hualan Biological Engineering Co., Ltd. | 64 | 1 |
| Shanghai Kehua Biological Engineering Co., Ltd. | 65 | 1 |
| Beijing Tiantan Biological Products Co., Ltd. | 66 | 1 |
| Beijing SL Pharmaceutical Co., Ltd. | 67 | 1 |
| Shanghai RAAS Blood Products Co., Ltd. | 68 | 1 |
| Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical Manufacturing in South Korea | 69 | 9 |
| South Korean Biopharmaceutical Industry | 69 | 1 |
| Market Size for South Korean Biopharmaceuticals | 70 | 1 |
| Evolution of the Biopharmaceutical Industry in South Korea | 71 | 1 |
| Korean Free Trade Agreement with the US | 71 | 1 |
| Drivers Affecting Biopharmaceuticals in South Korea | 72 | 1 |
| Korea/US Free Trade Agreement | 72 | 1 |
| Punishment Systems and Price Reduction | 72 | 1 |
| Government Initiatives for the Development of the Biopharmaceutical Industry | 72 | 1 |
| Major R&D Achievements in South Korea | 72 | 1 |
| South Korea s Strategic Advantage over India and China | 72 | 1 |
| Competitive Landscape | 73 | 1 |
| Celltrion | 73 | 1 |
| LG Life Sciences | 74 | 1 |
| Hanwha Chemical | 75 | 1 |
| ISU Abxis | 76 | 1 |
| Green Cross | 77 | 1 |
| Biopharmaceutical Manufacturing in India, China and South Korea - Appendix | 78 | 5 |
| Market Definitions | 78 | 1 |
| Abbreviations | 78 | 1 |
| Bibliography | 79 | 1 |
| Research Methodology | 80 | 2 |
| Coverage | 80 | 1 |
| Secondary Research | 81 | 1 |
| Primary Research | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 82 | 1 |
| Disclaimer | 82 | 1 |